

Express Mail No. EV333 998 619US

INFORMATION	Attorney Docket	STAN-214CIP
DISCLOSURE STATEMENT	First Named Inventor	KAY, MARK A.
	Application Number	10/642,362
	Confirmation No.	1635
	Filing Date	August 14, 2003
Address to:	Group Art Unit	1632
Mail Stop Missing Parts Commissioner for Patents	Examiner Name	Unassigned
P.O. Box 1450 Alexandria, VA 22313-1450	FOR PERSIST	ASMID VECTORS THAT PROVIDE ENT AND HIGH LEVEL GENE AND METHODS FOR USING THE

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-214CIP may be charged thereon.

> Respectfully submitted, **BOZICEVIC, FIELD & FRANCIS LLP**

Date: December 3, 2003

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Bret E. Field

Registration No. 37,620

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/642,362 INFORMATION DISCLOSURE Filing Date August 14, 2003 STATEMENT BY APPLICANT First Named Inventor KAY, MARK A. Art Unit 1632 **Examiner Name** Unassigned (use as many sheets as necessary) Sheet of 1 **Attorney Docket Number** STAN-214CIP

			U.S. PATENT D	OCUMENTS	
Examiner Initials'	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5,922,687	7-13-1999	Mann et al.	
-		US- 5985,847	11-16-1999	Carson et al.	
		116			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials'	No. ¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁸

Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
No.¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
·	NAKAI et al. "Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo" Journal of Virology, Aug. 2001, p. 6969-6976.	
	NAKAI et al. :Adeno-Associated Viral Vector-Mediated Gene Transfer of Human Blood Coagulation Factor IX Into Mouse Liver" <i>Bllod</i> , Vol. 91, No. 12 (June 15) 1998; pp. 4600-4607	
	YANT et al "Somatic Integration and Long-Term Transgene Expression In Normal and Haemophilic mice using a DNA Transposon System" <i>Nature Genetics</i> , Vol. 25, May 2000 pp. 35-41	
	MIAO et al. "Inclusion of the Hepatic Locus Control Region, an Intron and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in Vitro" <i>Molecular Therapy</i> , Vol. 1, No. 6, June 2000, Pp., 522-532	
	ACSADI et al. "Direct Gene Transfer and Expression into Rat Heart in Vivo" <i>The New Biologist</i> , Vol. 3, No. 1 (January) 1991: pp. 71-81	
	HICKMAN et al. "Gene Expression Following Direct Injection of DNA into Liver" <i>Human Gene Therapy</i> 5:1477-1483 (December 1994)	
•	WOLFF et al. "Direct Gene Transfer into Mouse Muscle in Vivo" <i>SCIENCE</i> , 23 March 1990, Vol. 247. pp. 1465-1468	
	Database BIOSIS, Accession No. 2001:314005 NAKAI et al. "Persistent hF.IX Expression in Mouse Hepatocytes from Episomal rAAV Circular Intermediates Does Not Rely on the Presence of AAV-ITR but the Structure of Expression Cassette Itself. Blood, Vol. 96., No. 11, part 1. pg 431a	
		Responsible for Stable Liver Transduction In Vivo" Journal of Virology, Aug. 2001, p. 6969-6976. NAKAI et al. :Adeno-Associated Viral Vector-Mediated Gene Transfer of Human Blood Coagulation Factor IX Into Mouse Liver" <i>Bliod</i> , Vol. 91, No. 12 (June 15) 1998: pp. 4600-4607 YANT et al "Somatic Integration and Long-Term Transgene Expression In Normal and Haemophilic mice using a DNA Transposon System" <i>Nature Genetics</i> , Vol. 25, May 2000 pp. 35-41 MIAO et al. "Inclusion of the Hepatic Locus Control Region, an Intron and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in Vitro" <i>Molecular Therapy</i> , Vol. 1, No. 6, June 2000, Pp., 522-532 ACSADI et al. "Direct Gene Transfer and Expression into Rat Heart in Vivo" <i>The New Biologist</i> , Vol. 3, No. 1 (January) 1991: pp. 71-81 HICKMAN et al. "Gene Expression Following Direct Injection of DNA into Liver" <i>Human Gene Therapy</i> 5:1477-1483 (December 1994) WOLFF et al. "Direct Gene Transfer into Mouse Muscle in Vivo" <i>SCIENCE</i> , 23 March 1990, Vol. 247. pp. 1465-1468 Database BIOSIS, Accession No. 2001:314005 NAKAI et al. "Persistent hF.IX Expression in Mouse Hepatocytes from Episomal rAAV Circular Intermediates Does Not Rely on the Presence of AAV-ITR but the Structure of Expression Cassette Itself.

Examiner		Date
Signature		Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.